Clinical Trial Update: Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating escalating doses of thalidomide in combination with bortezomib and high-dose melphalan for autologous stem cell transplant in multipl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Alkeran (melphalan)
• Thalomid (thalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: Hackensack Meridian Health | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-01-03